IMPORTANT MILESTONE REACHED – PHASE IIB-STUDY FULLY RECRUITED

The last patient has been recruited in the ongoing phase IIb clinical trial of STA363 for chronic disc-related low back pain. Recruitment is thereby completed. The patients will be followed for 12 months after inclusion. Final results from the study are expected to be available in Q4 2023 after the Company has compiled and analyzed data from all treated patients in the study.

Read more in the Press Release

Latest press releases

December 6, 2022

Stayble Therapeutics presents the ongoing phase 2b study at the European Congress on Clinical Trials in Pain

Stayble Therapeutics AB (“Stayble” or the “Company”) announces that the Company’s ongoing Phase 2b study has been accepted for poster presentation at the 4th European Congress on Clinical Trials in Pain (SOPATE2022). The Congress will be held in Vienna, Austria, on December 7-8, 2022.

Read more| Download PDF Download PDF
November 30, 2022

Stayble Therapeutics presents at ProHearings Capital Market Day on December 1 2022

On Thursday, December 1, Stayble Therapeutics AB (“Stayble” or the “Company”) will participate in ProHearing’s investor event. The Company’s CEO, Andreas Gerward, will give an investor presentation and answer questions in a moderated Q&A session following the presentation.

Read more| Download PDF

Financial reports

INTERIM REPORT Q3 2022 (SE)Download
INTERIM REPORT Q2 2022 (SE)Download
INTERIM REPORT Q1 2022 (SE)Download

Bridging the therapeutic gap

About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.

Our market

Treating the root cause of the disease. Not just the symptoms.

Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.

Healthy disc

An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.

DEGENERATED UNTREATED DISC

When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.

Treated disc

By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.

Read more

LET’S MEET UP

We are participating in several conferences and industry events every year. Please do not hesitate to contact us to meet up.

Upcoming events

No events planned at the moment

Upcoming events

Get in touch

We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you shortly.

info@stayble.se